Resources & Publications

The TriNav Infusion System was shown to significantly increase tumor penetration of embolic microspheres with improved sparing of normal liver tissue

Jaroch Study – Highlights: PEDD Significantly Increases Intra-Arterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model

MKT-0552 Jaroch Embolic Microsphere Study Marketing Pager

PEDD Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model

Jaroch et al, Embolic Microsphere (Journal of Vascular and Interventional Radiology)

Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model

Jaroch et al, Glass Microsphere (Journal of Vascular and Interventional Radiology)

The TriNav Infusion System was shown to significantly increase tumor penetration of embolic microspheres with improved sparing of normal liver tissue.

Jaroch Study: PEDD Significantly Increases Intra-Arterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model

MKT-0547 Clinical Summary Jaroch Preclinical Embolic Microsphere Study

TriNav How it Works Flashcard

TriNav How it Works Presentation

Complex Patient Flashcard

TriNav Core Presentation

Complex Patient Booklet

Quick Reference Guide

TriNav LV and TriGuide Spec Sheet

A Comprehensive Analysis of Claims* Defines the Complex Patient and TriNav’s Impressive Performance in This Challenging Group

TriNav Real World Evidence

Demonstrates increased T:N with TriNav even when improvement is not visible on every imaging modality

Case Snippet – Lobar Resin Y90 for Hypervascular NET

Demonstrates more homogenous perfusion and better tumor targeting with TriNav

Case Snippet – Lobar Resin Y90 for mCRC #2

Demonstrates delivery of cTACE using TriNav to improve the T:N ratio

Case Snippet – Selective cTACE for HCC in Decompensated Liver

Demonstrates TriNav’s ability to help overcome competitive flow from watershed to perfuse the entire tumor

Case Snippet – Selective Glass Y90 for Large HCC with Phrenic Watershed

Demonstrates TriNav trackability and improved tumor penetration

Case Snippet – Segmental Glass Y90 for HCC #2

Demonstrates improved T:N after resin Y90 treatment with TriNav LV

Case Snippet – Resin Y90 for Metastatic Leiomyosarcoma

Demonstrates improved tumor enhancement in both lobes after treatment with TriNav

Case Snippet – Lobar Resin Y90 for mCRC #1

Demonstrates improved T:N in lobe treated with TriNav

Case Snippet – Bi-Lobar Resin Y90 for Pancreatic NET

Demonstrates improved T:N after resin Y90 treatment with TriNav LV

Resin Y90 for Metastatic Leiomyosarcoma

Demonstrates more homogeneous/deeper glass Y90 penetration with TriNav

Case Snippet – Segmental Glass Y90 for HCC #1

Demonstrates increased T:N with TriNav even when improvement is not visible on every imaging modality

Lobar Resin Y90 for Hypervascular NET

Demonstrates homogenous perfusion and better tumor targeting with TriNav

Lobar Resin Y90 for mCRC #2

Demonstrates delivery of cTACE using TriNav to maximize the T:N ratio

Selective cTACE for HCC in Decompensated Liver

Demonstrates TriNav’s ability to overcome competitive flow from watershed to perfuse the entire tumor

Selective Glass Y90 for Large HCC with Phrenic Watershed

Demonstrates TriNav trackability and improved tumor penetration

Segmental Glass Y90 for HCC #2

Demonstrates improved T:N after resin Y90 treatment with TriNav LV

Resin Y90 for Metastatic Leiomyosarcoma

Demonstrates improved tumor enhancement in both lobes after treatment with TriNav

Lobar Resin Y90 for mCRC #1

Demonstrates improved T:N in lobe treated with TriNav

Bi-Lobar Resin Y90 for Pancreatic NET

Demonstrates more homogeneous/deeper glass Y90 penetration with TriNav

Segmental Glass Y90 for HCC #1

PEDD Significantly Improved Tumor Targeting Compared to a Traditional Microcatheter

Pasciak Study—Imaging Annex: The Impact of PEDD on Tumor to Normal Microsphere Distribution in Transarterial Radioembolization

Multi-Center Registry Study of the Safety, Feasibility, and Outcomes of Pressure-Enabled Drug Delivery in DEB-TACE for Patients with HCC

Kapoor Registry: Multi-Center Registry Study of the Safety, Feasibility, and Outcomes of PEDD in DEB-TACE for Patients with HCC

The TriNav Infusion System Significantly Increased Tumor Penetration of Glass Microspheres in Both Lobar and Selective Deliveries

Jaroch Study: Intra-arterial PEDD Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model

The TriNav Infusion System Significantly Increased Tumor Penetration of Glass Microspheres in Both Lobar and Selective Deliveries

Jaroch Study – Highlights: Intra-arterial PEDD Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model

Durable Response in Recurrent HCC After Y90 Treatment with TriNav

In a hepatic arterial model, a Pressure-Enabled Drug Delivery^TM device that generated turbulent particle flow demonstrated 62% better microsphere distribution to downstream arterial branches than a traditional microcatheter.

Favorable Particle-Fluid Dynamics With PEDD™ and SmartValve^® Technology

Microsphere Administration Using SmartValve Technology Was Associated With Improved Downstream Particle Distribution

van den Hoven Study: Innovation in Catheter Design for Intra-Arterial Liver Cancer Treatments Results in Favorable Particle-Fluid Dynamics

Demonstrates how the reflux protection and flow modulating properties of the TriNav can improve distribution.

Y90 Treatment via PEDD in Patient with HCC & Dosimetry Analysis Using MIM SurePlan Y90

Evidence demonstrates that the PEDD™ approach offers more precise tumor targeting, increased therapy delivery and better tumor response than traditional microcatheters.

PEDD™ Approach: Helping to Overcome Barriers to Effective Therapy Delivery

Helpful information on the device and its use.

TriNav Quick Reference Guide

See how SmartValve™ technology expands and contracts in sync with the cardiac cycle to help control flow and modulate pressure.

Ultrasound Imaging of TriNav Infusion System

Demonstration of Pressure-Enabled Drug Delivery™ (PEDD™) infusion performance.

TriNav Vascular Resistance Modeling

Demonstrates how TriNav was used to achieve deeper tumor penetration and less non-target activity in surrounding hepatic parenchyma.

Right Hepatic Glass Y90 Treatment Using TriNav in Patient with HCC

Demonstrates how TriNav can be used to deliver Y90 predictively and effectively to multicentric disease.

TriNav Improves Y90 Tumor Perfusion in Multicentric, Multilobar HCC

Demonstrates how TriNav’s SmartValve can be used to achieve stasis when performing DEB-TACE by modulating pressure and preventing reflux, and how PEDD can be used to achieve a good tumor response in DEB-TACE.

PEDD™ DEB-TACE in Patient with HCC

PEDD Significantly Increased T:N Ratio and Tumor Dose Compared to a Traditional Microcatheter

d’Abadie Study: PEDD Improves Tumor Targeting in Liver Radioembolization with Resin Microspheres

PEDD Significantly Increased Tumor Penetration and Improved Response When Used to Deliver DEM-TACE

Titano Study: A Retrospective Analysis of DEM-TACE Delivered via PEDD in Patients with HCC

PEDD Significantly Improved Tumor Targeting Compared to a Traditional Microcatheter

Pasciak Study: The Impact of PEDD on Tumor to Normal Microsphere Distribution in Transarterial Radioembolization

Compares Fluoro and CT angiography via conventional 5F angiographic catheter to TriNav.

Improved Perfusion via TriNav in Metastatic Renal Cell Carcinoma

Demonstrates how cTACE administered via PEDD may improve therapeutic delivery and response for a previously treated tumor.

Pressure-Enabled cTACE for HCC

Demonstrates how TriNav was used successfully in an MAA mapping procedure.

Y90 Mapping Procedure using TriNav in Patient with Metastatic Neuroendocrine Tumor

Displays pre- and post-treatment imaging of microsphere embolization when using TriNav in hypovascular leiomyosarcoma metastases.

Response to Microsphere Embolization Using TriNav in Hypovascular Tumors

Showcases a successful radiation segmentectomy performed using TriNav to treat a 5.6cm HCC tumor.

Right Hepatic Y90 Radiation Segmentectomy using TriNav in Patient with HCC

Showcases a successful DEB-TACE procedure performed using the TriNav, with selective segmental delivery.

Super-Selective DEB-TACE Performed Using TriNav in Patient with HCC

Improved Tumor Perfusion in Hepatocellular Carcinoma

The Use of TriNav to Improve Perfusion in Setting of Iatrogenic Complication

Compares SPECT-CT images showing tumor uptake when using TriNav vs standard microcatheter in a Y90 mapping procedure.

Improved Tumor Penetration via TriNav in a Y90 Mapping Procedure

The Impact of an Antireflux Catheter on Target Volume Particulate Distribution in Liver-Directed Embolotherapy: A Pilot Study

Pasciak et al (Journal of Vascular and Interventional Radiology)

Short-Term Imaging Response After Drug-Eluting Embolic Trans-Arterial Chemoembolization Delivered With the Surefire Infusion System For The Treatment Of Hepatocellular Carcinoma

Kim et al (PLOS One)

Surefire Infusion System Hepatocellular Carcinoma Registry Study Interim Results: A Multicenter Study of the Safety, Feasibility, and Outcomes of the SIS Expandable-Tip Microcatheter in DEB-TACE

Kapoor et al (Abstract, Journal of Vascular and Interventional Radiology)

End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis

Titano et al (CardioVascular and Interventional Radiology)

Displays the clinical utility of TriNav for accurate Y90 delivery.

Accuracy of TriNav in Y90 Mapping and Therapeutic Delivery

Demonstrates how TriNav’s PEDD approach can improve penetration and distribution in a Y90 mapping procedure.

Improved Tumor Uptake when Using TriNav in a Y90 Mapping Procedure

Indications for Use
The TriNav and TriNav LV Infusion Systems are intended for use in angiographic procedures. They deliver radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.^4,5

Contraindications
TriNav and TriNav LV Infusion Systems are not indicated for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).^4,5

Rx Only
For the safe and proper use of the TriNav and TriNav LV Infusion Systems, refer to their individual Instructions for Use.